Who has invested in ImmunoScape?

University of Tokyo Edge Capital, Anzu Partners, Leonardo DiCaprio, Enterprise Singapore are named among the investors backing ImmunoScape.

ImmunoScape Funding: $39M Raised, Series B (2022)

ImmunoScape funding overview

ImmunoScape is based in Singapore. ImmunoScape has raised $39M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in September 2022. The round record for ImmunoScape runs through 2022; nothing later has been disclosed. Investors on record include University of Tokyo Edge Capital, Anzu Partners, Leonardo DiCaprio, Enterprise Singapore. 4 distinct backers are named across the disclosed rounds.

ImmunoScape at a glance

Total raised: $39M
Latest round: Series B
Latest round date: September 2022
Headquarters: Singapore
Notable investors: University of Tokyo Edge Capital, Anzu Partners, Leonardo DiCaprio, Enterprise Singapore

Frequently asked about ImmunoScape funding

How much has ImmunoScape raised?: ImmunoScape has raised $39M in total disclosed funding across the rounds on record.
Who has invested in ImmunoScape?: University of Tokyo Edge Capital, Anzu Partners, Leonardo DiCaprio, Enterprise Singapore are named among the investors backing ImmunoScape.
What was the latest ImmunoScape funding round?: The most recent disclosed round is a Series B, announced in September 2022.
Where is ImmunoScape based?: ImmunoScape is based in Singapore.
When did ImmunoScape last raise?: The last disclosed ImmunoScape round closed in September 2022 at Series B.

We update the ImmunoScape record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Singapore and their backers are listed below.

ImmunoScape Funding: $39M Raised, Series B (2022)

ImmunoScape funding overview

ImmunoScape at a glance

Frequently asked about ImmunoScape funding

Companies related to ImmunoScape (19)

Browse related funding lists (7)